Experienced in Splenic Infarction

Dr. Jan Cerny

Hematology Oncology | Hematology | Oncology
Umass Memorial Medical Group Inc
119 Belmont St, 
Worcester, MA 
Accepting New Patients
22 Years of Experience
Experienced in Splenic Infarction
Umass Memorial Medical Group Inc
119 Belmont St, 
Worcester, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jan Cerny is a Hematologist Oncology specialist and a Hematologist in Worcester, Massachusetts. Dr. Cerny has been practicing medicine for over 22 years and is rated as an Experienced provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Cerny is currently accepting new patients.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Splenic Infarction.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Umass Memorial Medical Center/university Campus
Umass Memorial Healthalliance Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UMASS MEMORIAL MEDICAL GROUP INC
119 Belmont St, Worcester, MA 01605
Other Locations
UMASS MEMORIAL MEDICAL GROUP INC
55 Lake Ave N, Worcester, MA 01655

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: July 04, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth in Patients With Malignancy or Hematologic Disorders
Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth in Patients With Malignancy or Hematologic Disorders
Enrollment Status: Withdrawn
Publish Date: September 19, 2024
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
View 6 Less Clinical Trials

103 Total Publications

Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report.
Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report.
Journal: Leukemia research reports
Published: May 29, 2025
Similar Doctors
Advanced in Splenic Infarction
Dr. Ahmed Nadeem
Hematology Oncology | Hematology | Oncology
Advanced in Splenic Infarction
Dr. Ahmed Nadeem
Hematology Oncology | Hematology | Oncology

Prime Healthcare Services Landmark LLC

115 Cass Ave, Suite 2, 
Woonsocket, RI 
 (23.9 miles away)
401-597-5070
Languages Spoken:
English
See accepted insurances

Ahmed Nadeem is a Hematologist Oncology specialist and a Hematologist in Woonsocket, Rhode Island. Dr. Nadeem is rated as a Distinguished provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Childhood Iron Deficiency Anemia, Anemia, Myelodysplastic Syndrome (MDS), and Familial Colorectal Cancer.

Experienced in Splenic Infarction
Dr. Matthew I. Quesenberry
Hematology Oncology | Hematology | Oncology
Experienced in Splenic Infarction
Dr. Matthew I. Quesenberry
Hematology Oncology | Hematology | Oncology

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (37.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Quesenberry is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Quesenberry is rated as an Advanced provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Hemophilic Arthropathy, Hemophilia A, Acquired Hemophilia, Von Willebrand Disease (VWD), and Bone Marrow Aspiration.

Advanced in Splenic Infarction
Dr. Kenneth A. Bauer
Hematology Oncology | Oncology
Advanced in Splenic Infarction
Dr. Kenneth A. Bauer
Hematology Oncology | Oncology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (35.4 miles away)
617-754-8612
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kenneth Bauer is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Bauer is rated as a Distinguished provider by MediFind in the treatment of Splenic Infarction. His top areas of expertise are Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism (VTE), Embolectomy, and Thrombectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cerny's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile